Drug Trial Radar · NCT05687266
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,350
Actual
Start
Dec 29, 2022
Primary completion
Nov 1, 2027
Study completion Nov 1, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
Conditions
- NSCLC
Interventions
Datopotamab deruxtecanDrug
Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
DurvalumabDrug
Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
CarboplatinDrug
Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
PembrolizumabDrug
Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
CisplatinDrug
Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
PemetrexedDrug
Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
PaclitaxelDrug
Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive populationTime frame: Approximately 3 years
- Overall Survival (OS) in the non-squamous TROP2 biomarker positive populationTime frame: Approximately 5 years
- PFS by BICR in the non-squamous populationTime frame: Approximately 3 years
- OS in the non-squamous populationTime frame: Approximately 5 years
Locations
254 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Hot Springs, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Springdale, Arkansas
Research Site
Fountain Valley, California
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
Boulder, Colorado
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
St. Petersburg, Florida
Research Site
West Palm Beach, Florida
Research Site
Hinsdale, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Bettendorf, Iowa
Research Site
Iowa City, Iowa
Research Site
Waukee, Iowa
Research Site
Baton Rouge, Louisiana
Research Site
Covington, Louisiana
Research Site
Duluth, Minnesota
Research Site
Rochester, Minnesota
Research Site
Hannibal, Missouri
Research Site
Lincoln, Nebraska
Research Site
Lincoln, Nebraska
Research Site
Clifton Park, New York
Research Site
Asheville, North Carolina
Research Site
Canton, Ohio
Research Site
Columbus, Ohio
Research Site
Maumee, Ohio
Research Site
Tulsa, Oklahoma
Research Site
Portland, Oregon
Research Site
Salem, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
York, Pennsylvania
Research Site
Watertown, South Dakota
Research Site
Memphis, Tennessee
Research Site
Dallas, Texas
Showing 40 of 254 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.